Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898794 | 0.93 | ALDH1A1 (0.46) | TOP2APDE4BMAPT | |
| SCHEMBL8285046 | 0.89 | PDE4B (0.38) | TOP2APDE4BGPR119TP53MAPT | |
| SCHEMBL13902789 | 0.87 | GPR119 (0.42) | TOP2APDE4BGPR119PDE4DPDE4A | |
| SCHEMBL3907007 | 0.86 | TOP2A (0.46) | TOP2APDE4BGPR119PDE4DPDE4A | |
| SCHEMBL3151577 | 0.86 | TOP2A (0.47) | TOP2APDE4BGPR119TP53 | |
| SCHEMBL13902779 | 0.85 | PDE4B (0.41) | TOP2APDE4BGPR119PDE4DPDE4A | |
| SCHEMBL3903514 | 0.84 | BCL9 (0.40) | MAPT | |
| SCHEMBL3157312 | 0.83 | PDE4B (0.52) | PDE4BGPR119PDE4DPDE4APDE4C | |
| SCHEMBL3904231 | 0.83 | TOP2A (0.45) | TOP2APDE4BGPR119PDE4DPDE4A | |
| SCHEMBL3160242 | 0.83 | METAP1 (0.44) | TOP2APDE4BGPR119TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | TOP2A 4355/4885PDE4B 1956/4885GPR119 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.